Hydroxocobalamin
Level |
Direction |
Primary Outcome |
Patient/Process |
Setting |
Reference |
I
|
Neutral (Yellow)
|
Safety
|
Patient
|
SIM
|
Uhl W, Nolting A, Golor G, Rost KL, Kovar A. Safety of hydroxocobalamin in healthy volunteers in a randomized, placebo-controlled study. Clin Toxicol (Phila) 2006; 44 Suppl 1:17-28. Medline
|
III
|
Supportive (Green)
|
Survival & recovery
|
Patient
|
PH-Paramedic
|
Borron SW, Baud FJ, Barriot P, Imbert M, Bismuth C. Prospective study of hydroxocobalamin for acute cyanide poisoning in smoke inhalation. Ann Emerg Med 2007; 49(6):794-801, 801.e1. Medline
|
III
|
Supportive (Green)
|
Cyanide level improvement
|
Patient
|
Other
|
Dinh D, Rosini JM. Empiric treatment of cyanide toxicity in an enclosed-space fire survivor. J Emerg Nurs 2014; 40(3):282-5; quiz 293. Medline
|
III
|
Supportive (Green)
|
Survival
|
Patient
|
PH-Paramedic & MD
|
Fortin JL, Giocanti JP, Ruttimann M, Kowalski JJ. Prehospital administration of hydroxocobalamin for smoke inhalation-associated cyanide poisoning: 8 years of experience in the Paris Fire Brigade. Clin Toxicol (Phila) 2006; 44 Suppl 1:37-44. Medline
|
III
|
Neutral (Yellow)
|
Indication for use
|
Process
|
PH-Paramedic
|
Cumpston KL, Rodriguez V, Nguyen T, MacLasco A, Zin C, Rutherfoord Rose S, et al. Evaluation of prehospital hydroxocobalamin use in the setting of smoke inhalation. Am J Emerg Med 2021; 50:365–8. Medline
|
III
|
Neutral (Yellow)
|
Survival
|
Patient
|
ED-MD
|
Davies V, Turner J, Greenway M. Toxic inhalational injury. BMJ Case Rep 2020; 13(3). Medline
|
III
|
Neutral (Yellow)
|
Utility
|
Process
|
ED-MD
|
Mastenbrook J, Zamihovsky R, Brunken N, Olsen T. Intraosseous administration of hydroxocobalamin after enclosed structure fire cardiac arrest. BMJ Case Rep 2021; 14(3). Medline
|
III
|
Opposes (Red)
|
Development of acute kidney injury
|
Patient
|
ICU
|
Pruskowski KA, Britton GW, Cancio LC. Outcomes after the administration of hydroxocobalamin. Int J Burns Trauma 2020; 10(5):231-36. Medline
|